INTRODUCTION
RalGDS/AF6 binding domains were produced as previously described (26) . Luciferase assays were performed by co-transfection of LNCaP cells with 0.125 µg Gal4-Elk, 1.25 µg 5XGal4-Luc and 1 µg pcDNA3 encoding the indicated gene, using Fugene6 (Roche) (14) . After 24 hr, cells were serum starved overnight and luciferase activity determined as described.
Ras Protein Binding Assay--This assay was completed as described previously (26) . Briefly, 293T cells were transfected with vectors encoding FLAG-MR-GEF, FLAG-PDZ-GEF or FLAG-GRP3 using NovaFECTOR (Venn Nova Inc.). After 48 h, cells were lysed, and mixed with ~20 µg GST-Ras-fusion proteins bound to glutathione-agarose beads. This slurry was tumbled for 2 h at 4 °C and then the beads were washed 4 times with Ras buffer (20 mM Tris-HCl, pH 7.6, 5% glycerol, 50 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, and 1 mM DTT) and the bound GEFs were visualized by SDS-PAGE immunoblotting. For the assay of MR-GEF or PDZ-GEF as Ras effectors, the glutathione-agarose-immobilized GST-Ras proteins (~10 µg) were loaded with 100 µM GDP or GTPγS and the 293T cell lysates expressing FLAG-tagged MR-GEF, MR-GEF∆cat or PDZ-GEF were prepared with Ras buffer containing 5 mM MgCl 2 instead of EDTA.
Non-Radioactive
In vivo Exchange Assay--293T cells were transfected with 750 ng of pFLAG-CMV2-Rap1A, RalA or H-Ras and 750 ng of the indicated GEF using 8 µl of NovaFECTOR/60-mm dish. After 24 h, serum was removed for another 18 h. Cells were rinsed twice in phosphate buffered saline, lysed with Ral buffer (0.5 ml/dish; 50 mM Tris-HCl, pH 7.4, 10% glycerol, 200 mM NaCl, 2.5 mM MgCl2, 1% IGEPAL (Sigma), aprotinin (0.05 TIU/ml), 1 mM PMSF), and cleared by centrifugation for 10 min at 12,000 x g. Approximately10 µg of GST-Raf (residues 2-140; for Rap1A and H-Ras) or -RID (residues 648-778; for RalA) bound to 35 µl of glutathione-agarose beads (50% slurry) were rinsed twice with Ral buffer and then tumbled with 400 µl of cell lysate for 1 h at 4 °C. The beads were washed 4 times with Ral buffer, omitting protease inhibitors. The activated FLAG-tagged GTPase bound to the GST-RA domain were visualized by immunoblotting Radioactive In vivo Exchange Assay --293T cells were transfected with 750 ng of pFLAG-CMV2-Rap and increasing amounts of pcDNA3 MR-GEF with and without 500 ng of MRas71L using NovaFECTOR (empty vector was used to equalize the amount of transfected DNA). After 18 hrs the media was changed to serum-free media and the cells were incubated for another 20 hrs. The media was changed to phosphate-free and serum-free media for 30 min, then 150 µCi of [ 32 P]-orthophosphate was added to each dish. After 2 hr of incubation the cells were lysed in 500 µl of lysis buffer (50 mM Hepes, pH 7.5, 500 mM NaCl, 6 mM MgCl 2 , 1% Triton X-100, 0.5% Deoxycholate, 0.05% SDS, 1 mM EDTA, 1 mM PMSF and aprotinin (0.05 TIU/ml)), cleared by centrifugation for 5 min at 12,000 x g, then precleared for 15 min at 4°C with 30 µl of protein A/G agarose (Santa Cruz Biotechnology, Inc.). The precleared lysate was tumbled with 10 µg of M2 anti-FLAG antibody (Sigma) for 30 min at 4 °C, then incubated with 30 µl of protein A/G agarose at 4°C. Bound proteins were washed 6 times with ice-cold Wash buffer (50 mM Hepes, pH 7.5, 500 mM NaCl, 5 mM MgCl 2 0.1% Triton X-100 and 0.005% SDS). Twenty µl of Elution buffer (2 mM EDTA, 5 mM DTT, 1mM GDP, 1mM GTP and 0.2% SDS) were added to the beads which were incubated for 20 min at 68°C. Ten µl of the supernatant were spotted on PEI cellulose TLC plates (Bakerflex, Inc.) and run in 0.75 M KH 2 PO 4 . GDP and GTP spots were quantitated with a β-scanner (Ambis, Inc.) and % GTP was calculated as [GTPcpm/(GDPcpm x 1.5)+GTPcpm] x 100. Levels of MR-GEF expression were determined by immunoblotting with a MR-GEF specific rabbit polyclonal antibody raised against residues 1-77. Bands of MR-GEF were quantitated using ECL reagents and Scion Image version 1.6c.
Coimmunoprecipitation. 293T cells were co-transfected with 2 µg of either pFLAG-CMV2-MR-GEF or pFLAG-CMV2-MR-GEF∆cat and 2 µg of either pCGN-M-ras(wt) ,-M-ras(71L),-Hras(61L) or R-ras(87L) using 20 µl of NovaFECTOR/100-mm dish. After 48 h the cells were lysed in 1 ml of lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1% IGEPAL, 1 mM EGTA, 100 mM NaF, 10 % glycerol, 1 mM PMSF and aprotinin (0.05 TIU/ml)). Cellular debris was removed by a 3 min, 13,000 x g spin, and the cellular lysate was precleared for 15 min at 4 °C with 30 µl of protein A/G-agarose. The precleared lysate was
RESULTS

Identification and tissue distribution of multiple putative novel GEF cDNAs
Due to the relatively small number of CDC25 homology domain-containing family GEFs currently existing to regulate the Ras subfamily of GTPases, we used the SCR2 domain of GRF1 to search the NCBI expressed sequence tag and non-redundant databases for additional family members. We then re-screened the databases using the isolated sequences to identify further cDNAs. Using this approach we identified multiple hits. These included: 1) a cAMP-activated GEF, Epac, subsequently described by others (21,32); 2) GRP3 which closely resembles the Ca 2+ /diacylglycerol activated Ras GEF, GRP1, and the related Rap1 GEF, GRP2 (19, 20, 31) (Fig.   1 ); 3) MR-GEF shared strongest homology with the cAMP activated Rap GEF Epac and to 4) another novel putative GEF, PDZ-GEF. Characterization of a novel family of Ral GEFs, RalGPS, has been described elsewhere (26) . As seen in Fig 1, all of these GEFs shared sequence homology in REM/SCR 0, SCR 1-3 as well as two other regions that are boxed and referred to here as SCR 4 and 5. SCR4 contains a highly conserved I/VNF motif that sits in a hydrophobic groove formed by SCR 0 (29) while SCR 5 represents a highly conserved C-terminal sequence.
GRP3 mRNA is ubiquitously expressed and is most abundant in kidney, brain, lung and heart (HUGE protein database, Kazusa DNA Research Institute, Chiba, Japan). To determine the tissue distribution of MR-GEF and PDZ-GEF, cDNAs were used to probe a multi-tissue northern blot. As shown in Fig. 2 , both GEF messages were most abundantly expressed in brain with detectable levels in various other tissues, many being of epithelial origin.
MR-GEF and PDZ-GEF are Rap family exchange factors
Since the above sequence alignment predicted that MR-GEF and PDZ-GEF should act as
GEFs for Ras family GTPases we determined their substrate specificity. To do this we initially took advantage of the fact that GEFs bind with high affinity to nucleotide-free GTP-binding proteins (35) . Following the expression of FLAG epitope tagged GEFs in 293T cells, nucleotide-free GST-Rap1A was found to precipitate both GEFs from cell lysates (Fig. 3A) .
GST-Rap2B also precipitated PDZ-GEF and weakly MR-GEF suggesting that these GEFs might be Rap-specific exchange factors (Fig 3A) . There was no significant interaction with other GTPases indicating that they were unlikely to be MR-GEF and PDZ-GEF substrates. In contrast, GRP3 bound to all GTPases tested in a non-specific manner 2 .
To confirm that the GEFs that bound a particular Ras protein in vitro also induced nucleotide exchange in vivo, we transiently co-expressed various GEFs along with epitope- 
Rap GEFs can induce Elk-1 activation in LNCaP cells
Since Rap1 is required for cyclic AMP-induced B-Raf/ERK activation in PC12 and LNCaP cells (7, 8) , we next examined whether various Rap GEFs could mimic Rap1 in LNCaP prostate cancer cell line to promote downstream Elk-1 activation. As seen in Fig. 4 , overexpression of MR-GEF, PDZ-GEF, GRP3, C3G or Smg GDS to varying degrees mimicked the ability of activated Rap1A(63E) to promote Elk-1-induced luciferase expression. These studies demonstrate that the novel Rap1 exchange factors are biologically active following exogenous expression. We presume that the greater activation response of Elk-1 to GRP3 than other Rap
GEFs is due to its dual role as both a Ras and Rap1 GEF.
M-Ras-GTP associates with MR-GEF
The subcellular localization and activity of previously characterized GEFs is modulated by various regulatory domains. Examination of Ras family GEFs indicated that MR-GEF and PDZ-GEF both contain a region immediately N-terminal to SCR 1 that shares sequence homology with the Ras associating (RA) domains of RalGDS and AF6 (Fig. 1C) . These domains interact with the effector-binding loop of active GTP-bound Ras proteins (37) . To determine if the putative RA domains in MR-GEF and PDZ-GEF interact with Ras proteins in vitro, GST-Ras fusion proteins loaded with non-hydrolyzable GTP analog, GTPγS were incubated in the presence of millimolar MgCl 2 with 293T cell lysates containing FLAG-tagged MR-GEF or PDZ-GEF. In the presence of MgGTP there should be no significant association of GTPases with GEF catalytic domains (38) . As shown in Fig. 5A , PDZ-GEF specifically bound to Rap1A and Rap2B. Since Rap proteins did not bind to C3G or MR-GEF under similar conditions, in the presence of GTP, the interaction of PDZ-GEF with Rap1A would appear to be via its RA rather than catalytic domain.
The RA domain of MR-GEF is not as highly conserved with those of RalGDS and AF6
as is PDZ-GEF (see Fig 1C) . However, MR-GEF was found to specifically associate with MRas (Fig. 5A ). This in vitro interaction occurred in a GTP-dependent manner (Fig. 5B ) and was not a result of M-Ras binding to the catalytic domain since an N-terminal fragment, MR-GEF∆cat truncated in SCR 1 (see Fig. 1A ) retained its ability to bind M-Ras-GTP (Fig. 5C ).
This N-terminal region encompasses the RA domain of MR-GEF.
In vivo association with M-Ras inhibited MR-GEF-induced Rap1 activation
Overall, the in vitro experiments implied that MR-GEF is a specific M-Ras effector.
Hence, we tested whether M-Ras could interact with MR-GEF in vivo. Following co-expression in 293T cells, MR-GEF co-precipitated with constitutively activated M-Ras(71L) (Fig. 6A ). In contrast, the predominantly GDP-bound M-Ras(wt) could not efficiently precipitate MR-GEF demonstrating that the co-precipitation of M-Ras and MR-GEF in vivo is GTP dependent.
Additionally, MR-GEF failed to interact with activated H-Ras(61L) or R-Ras(87L) again
suggesting that the interaction with M-Ras is specific. As seen in vitro, M-Ras(71L) associated in vivo with MR-GEF∆cat (Fig 6B) . Thus, the N-terminal region of MR-GEF is responsible for the in vivo interaction with M-Ras-GTP and it may serve as a regulatory region of MR-GEF function.
Since binding of Ras-GTP to RalGDS results in activation of Ral (39) A sequence homology search of the DNA databases has now revealed several additional members. We report here that putative exchange factors MR-GEF and PDZ-GEF activate Rap1 while a third, GRP3 activates Rap and Ras. An additional Ral GEF family "RalGPS" has been described elsewhere (26) . We found that MR-GEF and PDZ-GEF contain RA domains. Rap1A unless cAMP is present (21) . During the completion of this manuscript it was reported that the presence of cAMP or cGMP allowed PDZ-GEF to activate H-Ras in vivo without affecting Rap1 activation (47) . We saw no binding of PDZ-GEF to H-Ras in vitro and no activation of H-Ras by PDZ-GEF in the absence of cAMP in vivo, suggesting that H-Ras activation by PDZ-GEF is highly dependent on cyclic nucleotides and that they must act by permitting/promoting H-Ras-GEF association. PDZ-GEF is not the only example of a Rap1 GEF that also works on Ras. We found that GRP3 also activates both Rap1 and H-Ras and is consistent with reports indicating that Ras and Rap1 are concomitantly activated by mitogens (10, 52) . Like GRP1 and GRP2, GRP3 contains EF hands and a C1 domain suggesting that it is regulated by calcium and/or diacylglycerol. Although we have seen strong activation of H-Ras and Rap1 by GRP3 under serum-starved conditions it will be interesting to study whether activation by calcium and/or diacylglycerol regulates the specificity of GRP3 for H-Ras and
Rap1 as cAMP appears to do with PDZ-GEF.
The presence of RA domains in PDZ-GEF and MR-GEF suggests a novel mechanism of regulating the activity and/or specificity of Rap GEFs. The binding of Rap1 or 2 to the RA domain of PDZ-GEF may modulate its activity as part of a regulatory feedback mechanism. To date, regulation of PDZ-GEF activity by Rap1-GTP has not been reported. The C-terminus of the MR-GEF RA domain is poorly conserved with the "classical" RA domains of RalGDS and AF-6 (Fig. 1C) . However, the ability of M-Ras to bind the N-terminal regulatory domain of MR-GEF in a GTP dependent manner together with its ability to inhibit the activation of Rap1 by MR-GEF strongly suggest that association with the RA domain inhibits MR-GEF activity.
Additionally, it was interesting to find the putative RA domain of MR-GEF is conserved in two other GEFs. In fact, the Rap1 GEF Epac2 and the putative exchange factor Link GEFII contain considerable homology to MR-GEF beyond their RA and CDC25 homology domains (Fig 1C) .
This suggests that there is a family of Rap GEFs sensitive to M-Ras or others Ras protein regulation. As mentioned above, association of M-Ras with MR-GEF appears to inhibit Rap activation. Such negative regulation is seems logical given previous studies on these two
GTPases. M-Ras, like the classical Ras proteins, induces cellular transformation of 3T3 fibroblasts (14,15); whereas, Rap1 was initially discovered as a suppressor of K-Ras-induced transformation, thus antagonizing Ras functions. It has similarly been shown to antagonize T cell activation (53) . Under this scenario, it is reasonable to speculate that activation of M-Ras could be responsible for the negative regulation of the Rap1 pathway through its association with the RA domain of Rap GEFs. The lack of activated Rap1 would lead to the disassociation of the inactive Rap-Raf1 complex leaving Raf1 free for activation by M-Ras or other Ras proteins. As proteins (16) , such a mechanism may apply to several systems where Rap-Ras pathways result in different physiological outcomes. Currently, this hypothesis is under investigation.
Regulation of downstream GTPases by Ras was originally described for a family of Ral exchange factors (RalGDS) that contain C-terminal RA domains (34) . This interaction serves to recruit Ral GEFs to the membrane where they contact and activate the Ral GTPase. It is interesting to note that MR-GEF and PDZ-GEF have RA domains immediately N-terminus to their catalytic domains. Such insertions of regulatory domains within their catalytic domains may be a means of modulating the activity as well as the location of the catalytic domain.
Although the inhibitory role of M-Ras in Rap1 activation by MR-GEF supports this idea, further studies will be required to clarify their role. It will also be interesting to determine whether Rap1/2 interaction with the RA domain of PDZ-GEF results in similar effect. MR-GEF and PDZ-GEF join a growing list of proteins containing putative Ras associating domains for which the physiological relevance/function remains to be established (54, 55) .
In contrast to the Ras/Rap1 antagonism described above, Rap1 can activate ERK in certain cell types (7, 8) . This activation is dependent on the presence of the Rap1 effector B-Raf, which can activate the ERK pathway leading to downstream Elk-1 activation. We have shown
here that over-expression of Rap GEFs can promote Elk1-induced gene expression in LNCaP cells. Multiple agents that signal via growth factor receptors, cAMP or Ca 2+ have been reported to promote the growth of prostate cells (56, 57) . Further, Chen et al have reported that EGF and cAMP can cooperate to activate ERK in a Rap1-dependent manner (8) . Since GEFs are the major link between receptors and Ras protein activation it will be interesting to determine which of the various Rap GEFs are responsible for prostate cell growth.
In 
